Online inquiry

IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2511MR)

This product GTTS-WQ2511MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CALCRL gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001271751.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10203
UniProt ID Q16602
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2511MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7190MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ4889MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ13645MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6719MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ5006MR IVTScrip™ mRNA-Anti-GP, c4G7-N(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA c4G7-N
GTTS-WQ15771MR IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA WX-G250
GTTS-WQ9967MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA KBSA301
GTTS-WQ5094MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW